Is there a correlation between raised erythropoietin and thrombotic events in sickle-cell anaemia?

Lancet

Volumn 352, Issue 9127, 1998, Pages 566-567

  Dale, George L ^a   Alberio, Lorenzo ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN;

ADULT; CHILD; HUMAN; PRIORITY JOURNAL; SHORT SURVEY; SICKLE CELL ANEMIA; STROKE; THROMBOCYTE; THROMBOGENESIS; THROMBOSIS;

EID: 0032529529     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)11506-9     Document Type: Note

References (31)

1. 1 Beutler E. The sickle cell diseases and related disorders. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, eds. Williams haematology. New York: McGraw-Hill, 1995: 616-50.
2. 2 Bunn HF. Mechanisms of disease - pathogenesis and treatment of sickle cell disease. N Engl J Med 1997; 337: 762-69.
3. 3 Francis RB, Johnson CS. Vascular occlusion in sickle cell disease: current concepts and unanswered questions. Blood 1991; 77: 1405-14.
4. 4 Balkaran B, Char G, Morris JS, Thomas PW, Serjeant BE, Serjeant GR. Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr 1992; 120: 360-66.
5. 5 Powars D, Wilson B, Imbus C, Pegelow C, Allen J. The natural history of stroke in sickle cell disease. Am J Med 1978; 65: 461-71.
6. 6 Glauser T A, Siegel MJ, Lee BCP, DeBaun MR. Accuracy of neurological examination and history in detecting evidence of MRI-diagnosed cerebral infarctions in children with sickle cell hemoglobinopathy. J Child Neurol 1995; 10: 88-92.
7. 7 Francis RB. Platelets, coagulation and fibrinolysis in sickle cell disease: their possible role in vascular occlusion. Blood Coagul Fibrinolysis 1991; 2: 341-53.
8. 8 Houston PE, Rana S, Sekhsaria S, Perlin E, Kim KS, Castro OL. Homocysteine in sickle cell disease: relationship to stroke. Am J Med 1997; 103: 192-96.
9. 9 French JA, II, Kenny D, Scott JP, et al. Mechanisms of stroke in sickle cell disease: sickle erythrocytes decrease cerebral blood flow in rats after nitric oxide synthase inhibition. Blood 1997; 89: 4591-99.
10. 10 Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 1997; 337: 1584-90.
11. 11 Pegelow CH, Adams RJ, McKie V, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr 1995; 126: 896-99.
12. 12 Serjeant GR. Chronic transfusion programmes in sickle cell disease: problem or panacea. Br J Haematol 1997; 97: 253-55.
13. 13 Chaplin H, Alkjaersig N, Fletcher AP, Michael JM, Joist JH. Aspirin-dipyridamole prophylaxis of sickle cell disease pain crises. Thromb Haemost 1980; 43: 218-21.
14. 14 Greenberg J, Ohene-Frempong K, Halus J, Way C, Schwartz E. Trial of low doses of aspirin as prophylaxis in sickle cell disease. Pediatr Pharmacol Therapeut 1983; 102: 781-84.
15. 15 Semple MJ, Al-Hasani SF, Kioy P, Savidge GF. A double-blind trial of ticlopidine in sickle cell disease. Thromb Haemost 1984; 51: 303-06.
16. 16 Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; ii: 1175-77.
17. 17 Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients recieving haemodialysis. BMJ 1990; 300: 573-78.
18. 18 Erslev AJ. Erythropoietin. N Engl J Med 1991; 324: 1339-44.
19. 19 Cases A, Escolar G, Reverter JC, et al. Recombinant human erythropoietin treatment improves platelet function in uremic patients. Kidney Int 1992; 42: 668-72.
20. 20 Ishibashi T, Koziol JA, Burstein SA. Human recombinant erythropoietin promotes differentiation of murine megakaryocytes in vitro. J Clin Invest 1987; 79: 286-89.
21. 21 Wolf RF, Peng J, Friese P, Gilmore LS, Burstein SA, Dale GL. Erythropoietin administration increases production and reactivity of platelets in dogs. Thromb Haemost 1997; 78: 1505-09.
22. 22 Wolf RF, Gilmore LS, Friese P, Downs T, Burstein SA, Dale GL. Erythropoietin potentiates thrombus development in a canine arteriovenous shunt model. Thromb Haemost 1997; 77: 1020-24.
23. 23 Sherwood JB, Goldwasser E, Chilcote R, Carmichael LD, Nagel RL. Sickle cell anemia patients have low erythropoietin levels for their degree of anemia. Blood 1986; 67: 46-49.
24. 24 Andre M, Bergmann P, Ferster A, Toppet M, Fondu P. Serum immunoreactive erythropoietin level: a new parameter for monitoring transfusion management of thalassemia. Nouv Rev Fran Hematol 1991; 33: 299-302.
25. 25 Adams RJ. Sickle cell disease and stroke. J Child Neurol 1995; 10: 75-76.
26. 26 Mueller-Soyano A, De Roura ET, Duke PR, et al. Pyruvate kinase deficiency and leg ulcers. Blood 1976; 47: 807-13.
27. 27 Palek J, Jarolim P. Hereditary spherocytosis, elliptocytosis and related disorders. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, eds. Williams hematology. New York: McGraw-Hill, 1995: 536-57.
28. 28 Akins PT, Glenn S, Nemeth PM, Derdeyn CP. Carotid artery thrombus associated with severe iron-deficiency anemia and thrombocytosis. Stroke 1996; 27: 1002-05.
29. 29 Lipski DA, Bergamini TM. Upper extremity arterial thrombosis associated with immunohemolytic anemia. Surgery 1996; 119: 354-55.
30. 30 Hirsh J, Dacie JV. Persistent post-splenectomy thrombocytosis and thromboembolism: a consequence of continuing anaemia. Br J Haematol 1996; 12: 44-53.
31. 31 Kooistra MP, van Es A, Marx JJ, Herstig ML, Struyvenberg A. Low-dose aspirin does not prevent thrombovascular accidents in low-risk hemodialysis patients during treatment with recombinant human erythropoietin. Nephrol Dial Transplant 1994; 9: 1115-20.